Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.64 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11833495 | 0.83 | EHMT2 (0.70) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL2618715 | 0.83 | EHMT2 (0.77) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| Ethylene SCHEMBL19138148 | 0.80 | EHMT2 (0.90) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL21174 | 0.79 | EHMT2 (1.00) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL29349787 | 0.79 | EHMT2 (1.00) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL27972393 | 0.79 | EHMT2 (1.00) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL11036195 | 0.79 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL19268265 | 0.79 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL21137448 | 0.79 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 | |
| SCHEMBL327697 | 0.79 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | claimed |
| EP-3475282-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | claimed |
| WO-2017220517-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | claimed |
| EP-3145934-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | Pfizer Inc. (US) | 2017-03-29 | — | — | EP | claimed |
| EP-3027221-A1 | BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES | PhaseRx, Inc. (US) | 2016-06-08 | — | — | EP | claimed |
| US-9340553-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2016-05-17 | — | — | US | claimed |
| WO-2016041022-A1 | SENSOR SCAFFOLD | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-03-24 | — | — | WO | claimed |
| WO-2015177668-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-26 | — | — | WO | claimed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | claimed |
| WO-2015017519-A1 | BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES | PHASERX, INC. (US) | 2015-02-05 | — | — | WO | claimed |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-04 | — | — | US | disclosed |
| WO-2024028258-A1 | CONJUGATES OF PSMA-BINDING MOIETIES WITH CYTOTOXIC AGENTS | PHILOCHEM AG (CH) | 2024-02-08 | — | — | WO | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-2750713-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20140030279-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | SPIROGEN SARL (CH) | 2014-01-30 | — | — | US | disclosed |
| US-20130266595-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2013055987-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| EP-0457250-A2 | Novel bifunctional linking compounds, conjugates and methods for their production | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266595-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BCL6B, DRD1 | EHMT2 2408/4885EHMT1 2270/4885APOBEC3G 3927/4885 |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | EHMT2 1362/4885EHMT1 1437/4885APOBEC3G 208/4885 |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | CNR2, CNR1, P2RY2 | EHMT2 3379/4885EHMT1 3727/4885APOBEC3G 2737/4885 |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | EHMT2 1992/4885EHMT1 2154/4885APOBEC3G 103/4885 |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | EHMT2 4766/4885EHMT1 4856/4885APOBEC3G 2825/4885 |
| US-20140030279-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | CD22, CD2, CD2BP2 | EHMT2 531/4885EHMT1 2068/4885APOBEC3G 229/4885 |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | CNR2, CNR1, P2RY2 | EHMT2 3379/4885EHMT1 3727/4885APOBEC3G 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.